Seeking Alpha
11 Jun 2026, 07:22 UTC · 13w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM. — Meeting a primary clinical endpoint is a critical success milestone that significantly increases the probability of regulatory approval.
+0.80IDEAYA is moving toward an RTOR NDA Accelerated Approval submission filing for darovasertib. — The transition to an NDA filing indicates a clear path toward commercialization and potential revenue generation.
+0.60Upcoming catalysts include label expansion data for HLA*A2-positive mUM and neoadjuvant/adjuvant melanoma updates. — Label expansion increases the total addressable market (TAM), providing further upside potential for the asset.
+0.30Continue reading
5 related stories
Search tags
The company expects to complete the darovasertib NDA filing submission in H2 2026. — While a clear timeline is helpful, the distant date (2026) limits the immediate short-term price catalyst effect.
Which stocks this story touches
The company maintains a Strong Buy rating following positive clinical data and progress toward an NDA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
5h ago
